和络舒肝片联合恩替卡韦对活动性代偿期乙肝肝硬化患者的临床疗效

目的观察和络舒肝片联合恩替卡韦对活动性代偿期乙肝肝硬化患者的临床疗效。方法 82例患者随机分为对照组和观察组,每组41例,对照组给予恩替卡韦,观察组在对照组基础上加用和络舒肝片,疗程6个月。检测临床疗效、HBV DNA载量、肝脾影像学指标(脾厚度、Dsv、Dpv)、肝纤维化指标(HA、Ⅳ-C、PC-Ⅲ、LN)、肝功能指标(ALB、ALT、AST、TBIL)、中医证候评分变化。结果观察组总有效率高于对照组(P<0.05)。治疗后,2组HBV DNA载量、肝脾影像学指标、肝纤维化指标、肝功能指标、ALT、AST、TBIL、中医证候评分降低(P<0.05),ALB升高(P<0.05),以观察组更明显(P<0.05)。结论和络舒肝片联合恩替卡韦可减缓活动性代偿期乙肝肝硬化患者肝脏纤维化速度,改善肝功能,抑制HBV DNA病毒复制。

Clinical effects of Heluo Shugan Tablets combined with entecavir on patients with hepatitis B virus-related active compensated liver cirrhosis

AIM To observe the clinical effects of Heluo Shugan Tablets combined with entecavir on patients with hepatitis B virus-related active compensated liver cirrhosis.METHODS Eighty-two patients were randomly assigned into control group(41 cases) for 6-month administration of entecavir, and observation group(41 cases) for 6-month administration of both Heluo Shugan Tablets and entecavir. The changes in clinical efficacy, HBV DNA loading, liver and spleen imaging indices(spleen thickness, Dsv, Dpv), liver fibrosis indices(HA, Ⅳ-C, PC-Ⅲ, LN), liver function indices(ALB, ALT, AST, TBIL) and TCM symptom scores were detected.RESULTS The observation group demonstrated higher total effective rate than the control group(P<0.05). After the treatment, the two groups displayed decreased HBV DNA loading, liver and spleen imaging indices, liver fibrosis indices, ALT, AST, TBIL and TCM symptom scores(P<0.05) and increased ALB(P<0.05), especially for the observation group(P<0.05).CONCLUSION For the patients with hepatitis B virus-related active compensated liver cirrhosis, Heluo Shugan Tablets combined with entecavir can slow down the speed of liver fibrosis, improve liver functions and inhibit the virus copy of HBV DNA.